Codex® HiCap RNA Polymerase

The burgeoning field of mRNA therapeutics holds immense promise for treating a wide range of diseases. However, current in vitro transcription (IVT) methods face limitations in safety and cost-effectiveness. Codex® HiCap RNA Polymerase is a revolutionary enzyme engineered to overcome these hurdles.

Codex® HiCap offers a significant leap forward in mRNA production safety. Traditional methods generate double-stranded RNA (dsRNA) as a byproduct, which can trigger unwanted immune responses. HiCap, however, is designed to produce significantly less dsRNA, minimizing this potential side effect. This paves the way for the development of safer and more efficacious mRNA-based therapies.

Beyond safety, HiCap delivers exceptional performance. It generates high yields of capped mRNA, even for long transcripts, while maintaining excellent mRNA integrity. This ensures the production of potent and effective mRNA-based therapeutics. Additionally, HiCap offers flexibility by seamlessly working with various commercially available cap analogs and uracil analogs, providing researchers with greater control over the final product.

Codex® HiCap RNA Polymerase represents a paradigm shift in mRNA production. Learn how its ability to deliver enhanced safety, cost-effectiveness, and performance is empowering researchers to unlock the full potential of mRNA therapeutics, paving the way for a new era of personalized medicine.